Research progress on immunotherapy based on NK cells for hepatocellular carcinoma.
- Author:
Xinyue ZHU
1
;
Yufu ZHOU
2
;
Shiguo ZHU
3
Author Information
1. Department of Immunology and Pathogenic Biology, School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
2. Department of Immunology and Pathogenic Biology, School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. *Corresponding authors, E-mail: zhouyufu@shutcm.edu.cn.
3. Department of Immunology and Pathogenic Biology, School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. *Corresponding authors, E-mail: zhushiguo@shutcm.edu.cn.
- Publication Type:Journal Article
- MeSH:
Humans;
Carcinoma, Hepatocellular/therapy*;
Liver Neoplasms/therapy*;
Immunotherapy;
Killer Cells, Natural;
Receptors, Natural Killer Cell;
Tumor Microenvironment
- From:
Chinese Journal of Cellular and Molecular Immunology
2024;40(1):80-88
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is well characterized as a heterogeneous disease. Its late-stage diagnosis and chemotherapy resistance make it one of the refractory tumors in China. Natural killer (NK) cells play a significant role in immune surveillance. However, NK cells become dysfunctional in the progression of HCC, leading to tumor immune escape. This article reviews the recent progress on different strategies of NK cell-based immunotherapy in treating HCC, including direct adoptive NK cell transfer, gene engineering in NK cell, NK cell receptor targeting, immunosuppressive microenvironment modification, and tumor toxicity enhancement by cytokines or traditional Chinese medicine. These NK cell-based strategies have shown promising therapeutic potential.
